Recent Advances in Oral Peptide or Protein-Based Drug Liposomes

Abstract

The high physiology and low toxicity of therapeutic peptides and proteins have made them a hot spot for drug development in recent years. However, their poor oral bioavailability and unstable metabolism make their clinical application difficult. The bilayer membrane of liposomes provides protection for the drug within the compartment, and their high biocompatibility makes the drug more easily absorbed by the body. However, phospholipids—which form the membranes—are subjected to various digestive enzymes and mucosal adhesion in the digestive tract and disintegrate before absorption. Improvements in the composition of liposomes or modifying their surface can enhance the stability of the liposomes in the gastrointestinal tract. This article reviews the basic strategies for liposome preparation and surface modification that promote the oral administration of therapeutic polypeptides.

Advanced application of nanotechnology in active constituents of Traditional Chinese Medicines

“…The inclusion of active compounds from TCMs can influence tissue distribution, enable liposomes to target designated sites, augment therapeutic efficacy, and diminish toxicity [ 262 ]. Liposomes have many advantages, including high biocompatibility, low cytotoxicity, and simple manufacturing processes, chemical versatility for hydrophilic, amphiphilic, and lipophilic compounds, and facile modulation of pharmacokinetic properties by compositional mediation [ 263 – 265 ].…”

Possible Approaches to Studying the Influence of Magnetic Fields and Mechanical Effects on the Physicochemical Properties of Aqueous IgG Colloids

“…Thirdly, proteins have great potential in the field of personalized medicine, since molecular biology makes it possible to create protein molecules that best suit the individual needs and characteristics of the patient. It is already clear that in the future protein drugs will have many new opportunities and prospects in the field of medicine [10][11][12][13]. For example, a new class of pharmaceutical protein drugs based on gradual technology has recently emerged [14].…”

Special Issue “Delivery Systems of Peptides and Proteins: Challenges, Status Quo and Future Perspectives”

“…Considering the vulnerability of liposomes along the digestive tract, improvements in the components of liposomes or surface modification were developed. The authors envisaged that deeper understanding of the processes involved in the oral absorption of liposomes could contribute to designing more efficient delivery systems and thus improving the bioavailability of oral polypeptides or proteins [ 13 ]. In addition to injectable administration, the transdermal drug delivery of biomacromolecules has also attracted extensive attention.…”